Stockreport

MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial – Hagens Berman

MacroGenics, Inc.  (MGNX) 
Last macrogenics, inc. earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.macrogenics.com
PDF SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses [Read more]